dc.creator | McKinley, Eliot Thomas | |
dc.date.accessioned | 2020-08-22T00:10:06Z | |
dc.date.available | 2011-04-14 | |
dc.date.issued | 2011-04-14 | |
dc.identifier.uri | https://etd.library.vanderbilt.edu/etd-03282011-092608 | |
dc.identifier.uri | http://hdl.handle.net/1803/11588 | |
dc.description.abstract | The use of 18FDG-PET imaging to predict treatment response to IGF-1R/IR targeted therapy in mouse models of human lung cancer is presented in this thesis. In vitro cell studies were first conducted to establish sensitivity to treatment with OSI-906 and changes in glucose metabolism in responding cells. In vivo xenograft studies demonstrated that reduced 18FDG-PET correlated with PI3K pathway inhibition and was able to predict tumor response to OSI-906 prior to changes in tumor volume could be ascertained. The in vivo imaging results were validated with molecular correlates. Based upon these results 18FDG-PET imaging appears to serve as a rapid non-invasive marker of IGF-1R/IR inhibition and should be explored clinically as a predictive clinical biomarker in patients undergoing IGF-1R/IR-directed cancer therapy. | |
dc.format.mimetype | application/pdf | |
dc.subject | Treatment Response | |
dc.subject | Medical Imaging | |
dc.subject | PET | |
dc.subject | FDG | |
dc.subject | IGF-1R | |
dc.title | Use of 18FDG-PET imaging to predict treatment response to IGF-1R/IR targeted therapy in lung cancer | |
dc.type | thesis | |
dc.contributor.committeeMember | Adam Anderson | |
dc.type.material | text | |
thesis.degree.name | MS | |
thesis.degree.level | thesis | |
thesis.degree.discipline | Biomedical Engineering | |
thesis.degree.grantor | Vanderbilt University | |
local.embargo.terms | 2011-04-14 | |
local.embargo.lift | 2011-04-14 | |
dc.contributor.committeeChair | H. Charles Manning | |